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This study presents a detailed analysis of HIV-1 populations isolated from total PBMC, plasma, CD4 T cells, CD8 T cells,
and monocytes/macrophages in 13 patients receiving HAART. Sequence analysis of the reverse transcriptase and protease
genes indicated that viral strains isolated from different blood leukocytes were genetically distinct in each subject. Notably,
HIV variants isolated from CD8 T cells were distantly related to strains derived from other blood cell types, providing
evidence for the strain-specific infection of CD8 T cells in vivo. Compartmentalization of drug resistance mutations in
specific blood cell types was observed in approximately 50% of patients. The prevalence of resistance mutations was higher
in either CD4 T cells or monocytes/macrophages in these subjects. However, CD8 T cells showed markedly lower levels
of viral drug resistance in these patients, indicating a lack of viral replication in this compartment. This study is the first to
demonstrate the differential distribution of HIV drug resistance in different blood cell types during HAART and provides newKey Words: HIV-1; HAART; HIV-1 drug resistance; compa
INTRODUCTION
The introduction of highly active antiretroviral therapy
(HAART) has led to a remarkable decline in HIV-associ-
ated morbidity and mortality in the developed world (Gu-
lick et al., 1997; Hammer et al., 1997; Palella et al., 1998).
A significant proportion of HIV-infected individuals re-
ceiving HAART develop undetectable plasma HIV-1 viral
RNA levels (50 copies/ml) (Hirschel and Opravil, 1999).
However, the emergence of drug-resistant HIV-1 is an
increasing limitation of antiretroviral therapy (Hirsch et
al., 1998). Of major concern is the rise of HIV-1 variants
resistant to multiple antiretroviral agents which are as fit
as or in some cases fitter than wild type virus (Caliendo
et al., 1996; Kosalaraksa et al., 1998). In addition, persis-
tently infected, nonactivated T-lymphocytes have been
demonstrated in individuals receiving HAART with unde-
tectable viral RNA in blood plasma (Wong et al., 1997a).
Latent viral reservoirs of this kind may reseed the body
and hinder attempts at HIV eradication.
During treatment with HAART, the selection of variants
with drug resistance mutations is determined by a bal-
ance of the selective advantages conferred by these
1 To whom correspondence and reprint requests should be ad-
dressed at Retroviral Genetics Laboratory, Center for Virus Research,
Westmead Millennium Institute, Westmead Hospital, University of Syd-339talization; CD8 T cells.
mutations in the presence of antiretroviral drugs and
their impact on replicative capacity. The independent
evolution of resistant variants in different anatomical
compartments, especially during the implementation of
multiple drugs with different pharmacokinetic parame-
ters, may have a strong influence on the eventual out-
come of HAART treatment. Several studies have shown
that drug concentrations in vivo can vary considerably
from one tissue type to another during antiretroviral treat-
ment (Kepler and Perelson, 1998; Wong et al., 1997a). In
addition, some compartments have been shown to be
poorly accessible by different antiretroviral drugs, includ-
ing cerebrospinal fluid (Hoetelmans, 1998), genital tract
secretions (Overbaugh et al., 1996), and lymphoid tissue
(Omrani and Pillay, 2000).
Although differences in the composition of viral popu-
lations recovered from plasma and peripheral blood
mononuclear cells (PBMC) have been described (Ro-
mano et al., 1999; Simmonds et al., 1991; Wang et al.,
2000), little is known about the molecular nature of viral
populations within individual blood cell types during
HAART. CD4 T cells are the principal target of HIV;
however, infection of other hematopoietic cells, including
CD8 T cells (Livingstone et al., 1996; Yang et al., 1998;
Saha et al., 2001; Imlach et al., 2001; McBreen et al.,
2001), monocytes (McElrath et al., 1991; Sonza et al.,
2001; Lambotte et al., 2000; Zhu et al., 2002) and macro-insights into the infection of CD8 T cells in vivo. © 2003
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phages (Collman et al., 1989; Gendelman and Meltzer,
1989; Englund et al., 1995; Orenstein et al., 1997), has
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also been demonstrated. Differential selective pressures
on viral strains within specific blood cell types may
influence the emergence of drug-resistant variants. The
identification of cell types that serve as drug-resistant
reservoirs is crucial for the long-term success of antiret-
roviral treatment strategies. In addition, a reduction in the
selective pressures that influence the emergence of
drug-resistant viral strains in a given compartment may
result in the predominance of wild-type virus capable of
reseeding the viral population during the suppression of
plasma viremia.
To investigate these features of HIV infection, we have
conducted a detailed analysis of HIV-1 populations iso-
lated from plasma, total PBMC, CD4 T cells, CD8 T
cells, and monocytes/macrophages in 13 patients receiv-
ing HAART, with particular emphasis on the cellular dis-
tribution of drug-resistant viral strains in vivo. Mutations
in the protease (PR) and reverse transcriptase (RT) genes
of virus from each compartment were analyzed to identify
cellular reservoirs of HIV-1 drug resistance and to clarify
the trafficking of viral strains between cell-free and cell-
associated blood compartments. The infection of CD8
T cells by HIV is of particular importance as antiviral
responses elicited by these cells are vital to the long-
term success of HAART. Therefore, we also sought to
investigate the nature of viral strains derived from this
blood cell compartment and to further clarify the circum-
stances of CD8 T cell infection during HAART.
RESULTS
Purity of cell separations
The effectiveness of the cell separation method was
assessed by fluorescence-activated cell sorting (FACS)
analysis. CD4 T cells and CD8 T cells obtained by
positive isolation were detached from the magnetic
beads and left to recover in culture overnight. Subse-
quent FACS analysis revealed that contamination by
other cell types in each fraction was very low. Figure 1
shows purity data obtained from analysis of separated
cell fractions derived from patient 1. The CD4 T cell
fraction contained only 2% of cells that did not express
the CD4 marker. In the CD8 T cell fraction only a
minimal percentage of cells (3%) did not express the CD8
marker. The purity of the monocyte/macrophage cell
fraction obtained by positive isolation could not be as-
sessed by FACS analysis because it was not possible to
detach cells from the beads. However, the purity of each
T cell fraction strongly supports the effectiveness of this
methodology. Analysis of proviral DNA extracted from
each cell fraction also provided evidence that separa-
tions were effective. In a number of patients the antiret-
roviral drug resistance mutations present in virus derived
from each cell type were notably different, indicating that
they were derived from a different source (Table 2). In
subjects with a homogeneous distribution of drug resis-
tance mutations in each compartment, cell-specific vari-
ations that were unrelated to drug-resistance were ob-
served in the protease and reverse transcriptase peptide
sequences (Table 3). Preliminary analysis of viral enve-
lope sequences also indicated that viral populations ob-
tained from different cell compartments were distinct
(data not shown).
Compartmentalization of drug-resistant viral strains in
different blood cell types occurs in some patients
during HAART
HIV-1 protease and reverse transcriptase gene se-
quences derived from different blood compartments
(plasma, total PBMC, CD4 T cells, CD8 T cells, and
monocytes/macrophages) were analyzed for drug resis-
tance mutations in 13 patients (Table 2). In 3 of 13
patients, PCR amplification of virus from the CD8 T cell
FIG. 1. FACS analysis of cells purified by positive selection from total PBMC of patient 1. (A) CD4 T cell fraction demonstrating 98% purity. (B) CD8
T cell fraction demonstrating 97% purity.
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and monocyte/macrophage fractions was unsuccessful.
The plasma viral load of these patients was either low
(patient 13) or below detectable level (400 copies/ml)
(patients 11 and 12) which suggested a reduction in the
prevalence of CD8 T cell and/or monocyte infection in
these viral load categories. Monocyte/macrophage cell
fractions were not isolated from patients 6 and 7 due to
paucity of samples.
The distribution of drug resistance mutations in differ-
ent blood compartments was similar in some patients
and variable in others. In 5 subjects (patients 1, 2, 5, 6,
and 9) drug resistance mutations in virus from each
compartment were almost or completely identical. How-
ever, cell-specific variations in the protease and reverse
transcriptase peptide sequences that were not related to
drug resistance were observed in these individuals (Ta-
ble 3). These patients had a range of plasma viremia
including high (100,000 copies/ml: patients 1, 2, and 5),
intermediate (64,500 copies/ml: patient 9), and below
detection (400 copies/ml: patient 6) viral loads. CD4
T cell counts ranged from very low (10/l blood: patient
1) to normal (520/l blood: patient 6).
In contrast to the patients above, the profile of drug
resistance mutations in virus from different blood com-
partments was notably different in other subjects. Pa-
tients 3, 4, 7, 8, and 10 provided evidence that distinct
viral populations harboring specific drug resistance mu-
tations were present in different blood compartments.
These patients had a range of plasma viremia and CD4
T cells counts (Table 1). In general, the compartmental
variation in protease drug resistance mutations was less
than that of the reverse transcriptase gene. The most
notable feature in each of these 5 patients was that virus
derived from the CD8 T cell compartment displayed a
marked reduction in resistance to protease and/or re-
verse transcriptase inhibitors. In patients 3, 4, and 10 a
number of drug resistance mutations present in the RT
region of virus from the CD4 T cell and monocyte/
macrophage fractions were absent in virus derived from
the CD8 T cell compartment (Table 2). Similarly, resis-
tance to both PR and RT inhibitors in CD8 T cells was
lower than that of the CD4 T cell and/or monocyte/
macrophage fractions in both patients 7 and 8 (Table 2).
The monocyte/macrophage fraction was the most
drug-resistant blood cell compartment in patients 3 and
8. Several resistance mutations present in the PR (L10I/L)
and RT (A62A/V and G190A) genes of the monocyte/
macrophage and plasma fractions in patient 3 were
absent in virus from the CD4 and CD8 T cell com-
partments. Resistance to RT inhibitors was similar in
virus from CD4 T cells and monocytes/macrophages in
patient 8; however, several PR resistance mutations
(K20V, M36I, A71I, and L90M) detected in monocytes/
macrophages and plasma were absent in the CD4 and
CD8 T cell fractions. In contrast to patients 3 and 8, the
CD4 T cell fraction was the most drug-resistant blood
cell compartment in patients 4 and 10. Additional muta-
tions in virus from the CD4 T cell fraction increased the
level of resistance to both PR and RT inhibitors com-
pared to other cellular compartments in patient 4 (Table
2). In patient 10, resistance to PR inhibitors was identical
in all three blood cell fractions but CD4 T cells con-
tained more resistance mutations to RT inhibitors (Ta-
ble 2).
The data above indicate that although cellular com-
partmentalization of drug-resistant viral strains was evi-
dent in 5 of 13 patients, no clear pattern of cell-depen-
dent accumulation of resistance was evident in these
subjects. Virus derived from CD4 T cells harbored
more drug resistance mutations in some patients, while
TABLE 1
Clinical Features of Study Participants
Patient
T-cell count (/l)
Viral load
(copies/ml) Antiretroviral drug history and year commencedCD4 CD8 CD4:CD8
1 8 (2%) 172 (43%) 0.047 100,000 1991: AZT, 3TC, ddI, IDV, d4T, ABV, SQV, EFV, NFV, RTV, LPV
2 14 (2%) 420 (60%) 0.034 100,000 1992: AZT, ddI, 3TC, d4T, SQV, ABV, RTV, IDV
3 200 790 0.25 100,000 1996: SQV, ddC, IDV, RTV, SQV, NVP, ddI, 3TC, NFV, ABV, d4T
4 16 (1%) n/a 87,700 1992: ZDV, 3TC, IDV, NFV, NVP, d4T, SQV, RTV, ddI, ABV, EFV, APV, LPV
5 60 900 0.067 100,000 1998: d4T, AZT, SQV
6 580 870 0.67 400 1996: d4T, SQV, ddC, 3TC, IDV, NFV, NVP, APV, ddI
7 320 (20%) 800 (50%) 0.4 60,200 1991: EFV, IDV, d4T, 3TC, ddC, ZDV, ddI, ABV, LPV
8 195 (13%) 1110 (74%) 0.18 1,510 1991: AZT, ddI, ddC, 3TC, d4T, NFV, NVP
9 135 (5%) 1647 (61%) 0.08 64,500 1990: ZDV, 3TC, SQV, ddI, NFV, RTV, d4T
10 360 (36%) 460 (46%) 0.78 400 1995: ZDV, ddI, IDV, EFV, NFV
11 1012 (22%) 2806 (61%) 0.36 400 1995: ZDV, ddI, 3TC, IDV, d4T, NVP
12 105 (7%) 675 (45%) 0.16 400 1997: ZDV, 3TC, AZT, d4T, ddI, SQV, RTV, EFV
13 437 (23%) 950 (50%) 0.46 5,730 1994: ddI, AZT, 3TC, ddC, SQV, d4T, ddI, NVP, NFV
Note. n/a, not available.
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TABLE 2
Comparison of HIV-1 Drug Resistance Mutations in Total PBMC to Those of Viral Populations from CD4 T Cells,
CD8 T Cells and Monocytes/Macrophages
Patient Source Protease resistance mutations
Change(s) in drug resistance
compared to total PBMC
Reverse transcriptase
resistance mutations
Change(s) in drug resistance
compared to total PBMC
1 PBMC L10I, K20I, M36I, M46I, L63P,
A71V, G73S, I84V, L90M, I93L
M41L, E44D, D67N, L74V, L100I,
K103N, V118I, L210W, T215Y, K219R
CD4 Identical to PBMC Identical to PBMC
CD8 L10I 3 L10V No change Identical to PBMC
Monocytes Identical to PBMC Identical to PBMC
Plasma Identical to PBMC Identical to PBMC
2 PBMC L10I, L63P, A71V, G73S, V77I,
L90M, I93L
M41L, D67E, T69S_V/T, L74I/V, V108I,
V179I, Y181C, L210W, T215Y
CD4 Identical to PBMC L74I/V 3 L74V () AZT/d4T
CD8 Identical to PBMC L74I/V 3 L74I () AZT/d4T
Monocytes Identical to PBMC L74I/V 3 L74V () AZT/d4T
Additional mutation: K101Q () All NNRTI
Plasma Additional mutation: K20I/K () All PR L74I/V 3 L74L/V No change
3 PBMC K20V, M46I/M, L63P, A71V,
G73S, V77I, I84V, L90M
A62A/V, L74L/V, V75I/V, F77F/L, K103K/
N, Y115F/Y, F116F/Y, Q151K/L/M/Q,
Y181C, M184V, G190A/G
CD4 Identical to PBMC Y181C 3 Y181C/Y () AZT
Absent mutations: A62A/V () All NRTI (except 3TC)
G190A/G () EFV/NVP
CD8 M46I/M 3 M46I/L No change L74L/V 3 L74V () AZT, d4T
K103K/N 3 K103N, Y115F/Y 3 Y115F No change
Absent mutations: A62A/V () All NRTI (except 3TC)
V75I/V () All NRTI [() d4T]
F77F/L, F116F/Y () All NRTI
Q151K/L/M/Q () All NRTI [() ABC
() 3TC/TDF]
Y181C () DLV/NVP () EFV
() AZT
G190A/G () EFV/NVP
Monocytes K20V 3 K20E/K/M/V No change G190A/G 3 G190A No change
Additional mutation: L10I/L () All PR
Plasma M46I/M 3 M46I No change V75I/V 3 V75I, F77F/L 3 F77L, Y115F/
Y 3 Y115F
No change
Additional mutation: L10I/L () All PR F116F/Y 3 F116Y, Q151K/L/M/Q 3
Q151M
No change
Additional mutations: V108I/V () All NNRTI
Absent mutations: L74L/V () ddI/ddC () ABC
K103K/N () All NNRTI
4 PBMC L10F, L24I, M36I, M46I, I54V,
L63P, V82A
D67N, K70K/R, L74V, A98G, K103N,
Y115F, Q151M/Q, Y181C, M184M/V,
G190A/G, T215F/I/S/T, K219Q
CD4 Additional mutations: K20K/R () All PR D67N 3 D67D/G/N/S () ddI/ddC
L90L/M () NFV () IDV/RTV/SQV L74V 3 L74L/V () AZT/d4T
() APV/LPV Y115F 3 Y115F/Y No change
Y181C 3 Y181C/W () AZT
Additional mutations: V75I/V () All NRTI [()d4T]
CD8 Identical to PBMC Y115F 3 Y115F/Y No change
Absent mutations: K70K/R () AZT () TDF
M184M/V () 3TC () ddI/ddC/
ABC
G190A/G () EFV/NVP
Q151M/Q () All NRTI [() 3TC/TDF]
Monocytes Identical to PBMC K70K/R 3 K70R, Q151M/Q 3 Q151M, No change
G190A/G 3 G190A, T215F/I/S/T 3
T215F
No change
K103N 3 K103H () All NNRTI
M184M/V 3 M184V () AZT/d4T/TDF
Plasma M46I 3 M46I/L No change K219Q 3 K219K/Q No change
Additional mutations: K20K/R () All PR Additional mutations: M41I/M () AZT
Absent mutations: K70K/R () AZT () TDF
Y115F () ABC
Q151M/Q () All NRTI [() 3TC/TDF]
M184M/V () 3TC () ddI/ddC/
ABC
G190A/G () EFV/NVP
5 PBMC L63A K103K/N, V179I
CD4 Identical to PBMC Identical to PBMC
CD8 Identical to PBMC Identical to PBMC
Monocytes Identical to PBMC Identical to PBMC
Plasma Identical to PBMC Identical to PBMC
6a PBMC L63P None
CD4 Identical to PBMC Identical to PBMC
CD8 Identical to PBMC Identical to PBMC
Plasma Identical to PBMC Identical to PBMC
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TABLE 2—Continued
Patient Source Protease resistance mutations
Change(s) in drug resistance
compared to total PBMC
Reverse transcriptase
resistance mutations
Change(s) in drug resistance
compared to total PBMC
7a PBMC L10F/L, V32I/V, M46L/M, L63L/
P, A71A/V, V82A/V
M41L, D67N, A98A/G, K103N, V118I/V,
M184V, L210W, T215Y
CD4 L63L/P 3 L63P No change Identical to PBMC
Absent mutation: V82A/V () IDV/NFV/RTV () APV/SQV/
LPV
CD8 Absent mutations: V32I/V () All PR [() APV] Absent mutations: A98A/G () All NNRTI
L10F/L, L63L/P, A71A/V () All PR V118I/V () All NNRTI
M46L/M () All PR [() NFV]
V82A/V () IDV/NFV/RTV () APV/SQV/
LPV
Plasma L10F/L 3 L10F, V32I/V 3 V32I No change A98A/G 3 A98G, V118I/V 3 V118I No change
M46L/M 3 M46L, L63L/P 3
L63P
No change Additional mutations: L74I () ddI/ddC () ABC
() AZT/d4T
A71A/V 3 A71V, V82A/V 3
V82A
No change V108I () All NNRTI
8 PBMC L63L/P M41L/M, E44D/E, A98S, K103K/N,
M184M/V, L210W, T215N/S/T/Y
CD4 Identical to PBMC M41L/M 3 M41L, T215N/S/T/Y 3
T215Y
No change
Absent mutation: E44D/E () 3TC
CD8 L63L/P 3 L63P No change M41L/M 3 M41L, E44D/E 3 E44D No change
K103K/N 3 K103N No change
M184M/V 3 M184V () AZT/d4T/TDF
T215N/S/T/Y 3 T215S () All NRTI [except 3TC]
Monocytes L63L/P 3 L63P No change M41L/M 3 M41L, K103K/N 3 K103N No change
Additional mutations: T215N/S/T/Y 3 T215Y No change
K20V, M36I, A71I () All PR M184M/V 3 M184V () AZT/d4T/TDF
L90M () NFV () SQV/RTV/ITV Absent mutation: E44D/E () 3TC
() APV/LPV
Plasma L63L/P 3 L63P No change M41L/M 3 M41L, K103K/N 3 K103N No change
Additional mutations: T215N/S/T/Y 3 T215Y No change
K20V, A71V, G73S () All PR M184M/V 3 M184V () AZT/d4T/TDF
L90M () NFV () SQV/RTV/ITV Absent mutation: E44D/E () 3TC
() APV/LPV
9 PBMC K20R, D30N, M36I, L63P, A71T,
N88D
M41L, E44A, D67N, K103N, V118I,
Y181C, L210W, T215Y, K219N
CD4 Identical to PBMC Identical to PBMC
CD8 Identical to PBMC Identical to PBMC
Monocytes Identical to PBMC Identical to PBMC
Plasma Identical to PBMC Identical to PBMC
10 PBMC L63P M41L/M, L210L/W, T215N/S/T/Y
CD4 Identical to PBMC Identical to PBMC
CD8 Identical to PBMC Absent mutations: M41L/M, L210L/W () All NRTI (except 3TC)
T215N/S/T/Y () AZT/d4T/ABC () ddI/
ddC/TDF
Monocytes Identical to PBMC Additional mutation: K70K/R () AZT () TDF
Absent mutations: M41L/M, L210L/W () All NRTI (except 3TC)
T215N/S/T/Y () AZT/d4T/ABC () ddI/
ddC/TDF
11b PBMC L10I, M36I, L63P, V77I, I93L M184M/V
CD4 Identical to PBMC Additional mutation: K103K/R () All NNRTI
Plasma Absent mutation: M36I () All PR Absent mutation: M184M/V () 3TC () ddI/ddC/
ABC
Additional mutation: K103K/N () All NNRTI
12b PBMC None K103R
CD4 Additional mutation: D30N () NFV Additional mutation: M230I () All NNRTI
Plasma Additional mutations: M46I/M () NFV/APV () IDV/SQV/LPV Additional mutations: K101E () All NNRTI
L63P () All PR V108I/V () All NNRTI
13b PBMC L63A/P/S, V77I, I93I/L A98S
CD4 Identical to PBMC Additional mutations: D67D/N, K219K/Q () AZT () ddI/ddC/d4T/
ABC/TDF
T215S/T () AZT () d4T/ABC/TDF
Plasma L63A/P/S 3 L63A No change Additional mutations: D67N, K219Q () AZT () ddI/ddC/d4T/
ABC/TDF
Additional mutations: L10V, I54V () All PR K70R () AZT () TDF
G48V () All PR [() SQV ()
NFV]
T215F () AZT/d4T/ABC () ddI/
ddC/TDF
V82A () IDV/NFV/RTV () APV/SQV/
TD
Absent mutation: I93I/L () All PR
Note. Nomenclature of drug resistance mutations: (i) single letter abbreviation preceding number indicates identity of wild-type/consensus amino
acid at given position; (ii) number represents position of amino acid in peptide chain of RT or PR enzyme; (iii) single letter abbreviation(s) following
number indicates substitute amino acid in mutant virus at given position. (), small increase; (), medium increase; (), large increase in the
level of resistance to specified antiretroviral drug in comparison to the general PBMC viral population; (), small decrease; (), medium decrease;
(), large decrease in the level of resistance to specified antiretroviral drug in comparison to the general PBMC viral population.
a Isolation of monocyte/macrophage cell fraction not performed due to paucity of sample.
b PCR amplification of virus in CD8 T cell and monocyte/macrophage cell fractions unsuccessful.
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monocytes/macrophages showed more drug resistance
in others. Nonetheless, it is clear that multiple blood cell
types harbored drug-resistant viral strains in these pa-
tients with the notable exception of CD8 T cells in
several cases.
Trafficking of drug-resistant viral strains between
cell-free and cell-associated viral compartments
during HAART: Analysis of viral clones from the
plasma and total PBMC viral populations
Clonal analysis of plasma and total PBMC viral popu-
lations was performed in 5 of 13 patients. The RT-PR
genes were sequenced in 20–25 viral clones from each
compartment. To best represent the group as a whole,
patients selected for this analysis had a range of differ-
ent characteristics including variable plasma viremia
and CD4 T cell counts. The pattern of viral drug resis-
tance in different blood compartments was very similar
in 2 of these patients (patients 1 and 2), but variable in
others (patients 3 and 4). Patient 11 was representative
of several subjects in which PCR amplification of proviral
DNA from CD8 T cells and monocytes/macrophages
was unsuccessful.
The distribution of drug resistance mutations in virus
from different blood compartments was almost identical
in patients 1 and 2 (Table 2). Similarly, there was little
variation in the drug resistance profile of viral clones
derived from the total PBMC and plasma compartments
of these patients (data not shown). Figure 2A shows
phylogenetic analysis of RT-PR sequences from viral
clones in the total PBMC and plasma compartments of
patient 1. Clonal sequences from both compartments
shared a high degree of genetic homogeneity. Viral
clones were also closely related to sequences derived
from the total viral population of each blood cell type.
This provided evidence that each blood cell compart-
ment contributed virus to the plasma and total PBMC
populations in patient 1. Figure 2B shows phylogenetic
analysis of RT-PR sequences from viral clones in the total
PBMC and plasma compartments of patient 2. The viral
clones of each compartment were also closely related to
each other, although a degree of segregation was evi-
FIG. 2. Distance neighbor-joining trees showing phylogenetic relationships between RT-PR nucleotide sequences derived from total PBMC viral
clones (‚), plasma viral clones (), and the major viral population from various blood cell types (CD4 T cells, CD8 T cells, and monocytes/
macrophages) in patients 1–4 (A–D) and patient 11 (E).
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dent. Total population sequences from CD4 T cells and
CD8 T cells were closely associated with PBMC
clones. In contrast, virus derived from the monocyte/
macrophage fraction was more distantly related to
PBMC clones, suggesting a reduced contribution to the
total PBMC viral population. The CD4 T cell and mono-
cyte/macrophage viral populations were closely associ-
ated with plasma-derived clones, providing evidence of
viral trafficking between these compartments. However,
there was less evidence of trafficking between CD8 T
cells and plasma in patient 2.
Patients 3 and 4 showed significant variation in the
drug resistance profile of viral clones derived from both
the total PBMC and plasma compartments (data not
shown). This correlated well with earlier data which
showed heterogeneity in the drug resistance profiles of
different blood compartments in these patients (Table 2).
In patient 3, eight viral clones from the total PBMC
compartment lacked a number of mutations conferring
resistance to both PR (M46I) and RT (V55I, F77L, Y115F,
F116Y, Q151M, M184V) inhibitors. These mutations were
present in virus isolated from the CD4 T cell and
monocyte/macrophage compartments but absent in vi-
rus from the CD8 T cell fraction (Table 2). Figure 2C
shows that this subset of eight clones was closely re-
lated to virus from CD8 T cells but phylogenetically
distinct from monocyte/macrophage and CD4 T cell
total population sequences. This indicated that CD8 T
cells contributed variants with reduced levels of drug
resistance to the total PBMC viral population. However,
virus from CD8 T cells was phylogenetically distinct
from all plasma viral clones in patient 3, suggesting a
minimal amount of viral trafficking between these com-
partments (Fig. 2C). Sequences from CD4 T cells and
monocytes/macrophages were more closely associated
with plasma viral clones, providing evidence for the traf-
ficking of drug-resistant variants (Fig. 2C).
In patient 4, viral clones from total PBMC clustered
into two different groups (Fig. 2D). Clones in the upper
group were closely related to virus derived from the
monocyte/macrophage and CD4 T cell compartments.
Clones in the lower group were related to virus from
CD8 T cells and lacked three primary RT resistance
mutations present in clones from the upper group
(Q151M, M184V, and G190A). These data suggest that
individual cellular compartments contributed distinct HIV
FIG. 2—Continued
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variants with characteristic profiles of drug resistance to
the total PBMC viral population. Virus derived from
CD8 T cells was less closely related to plasma viral
clones than virus from the monocytes/macrophage and
CD4 T cell compartments (Fig. 2D). This suggested a
reduced amount of trafficking between the CD8 T cell
and plasma viral populations.
In patient 11, PCR amplification of proviral DNA from
CD8 T cells and monocytes/macrophages was unsuc-
cessful (Table 2). This indicated a reduction in the cellu-
lar sources of virus in total PBMC. As a consequence,
the degree of variation in the drug resistance profile of
individual viral clones from the total PBMC compartment
was reduced in patient 11 (data not shown). Fifteen of 21
clones had identical drug resistance profiles. In contrast,
there was a larger degree of variation in the drug resis-
tance profiles of viral clones from plasma (data not
shown). This suggests that in addition to virus derived
from total PBMC, other sources of drug-resistant virus
may have contributed to the plasma viral population of
this patient. This was supported by the notable degree of
segregation evident between PBMC and plasma-derived
viral clones (Fig. 2E).
Analysis of viral clones from the plasma and total
PBMC compartments demonstrated the trafficking of
drug-resistant viral strains between individual blood cell
types and the plasma compartment in each of these
patients. These data also indicated that CD8 T cell
infection was productive in some patients (patients 1 and
2) but may be quiescent in other subjects where CD8
T cell variants were more distantly related to plasma viral
clones (patients 3 and 4). A variable degree of compart-
mentalization between cell-free and cell-associated virus
was observed in these five patients (Figs. 2A–2E). The
segregation of viral strains from the plasma and PBMC
compartments evident in some individuals was con-
firmed by phylogenetic analyses of total viral population
sequences (Figs. 3A–3J). These findings indicate that
while there was evidence of trafficking between the
plasma and PBMC compartments in all subjects, the
sources of cellular and plasma virus were variable in
some cases and may be related to the immunological
state of the patient.
HIV-1 strains isolated from CD8 T cells are
phylogenetically distinct from strains in other blood
cell types: Direct evidence for strain-specific
selection in CD8 T cells in vivo
Phylogenetic analysis of RT-PR sequences from pa-
tients 1–10 revealed that viral populations from individual
blood cell compartments were largely distinct from each
other and from their plasma counterparts (Fig. 3). This
was most evident in patients who displayed cellular
compartmentalization of drug resistance mutations (pa-
tients 3, 4, 7, 8, and 10). Most notably, virus isolated from
CD8 T cells was phylogenetically distinct in a number
of subjects, and branched separately from other blood
cell types (patients 1, 2, 3, 6, 8, and 10). In addition, when
CD8 T cell strains clustered with other cell type(s)
(patients 4, 5, 7, and 9), the branch lengths were different,
providing evidence of molecular differences in variants
harbored by CD8 T cells (Fig. 3). These data suggest
that CD8 T cell infection was strain dependent in these
patients. The relationships between viral sequences de-
rived from other blood compartments were variable in
different patients. Phylogenetic analyses were not per-
formed in patients 11, 12, and 13 because PCR amplifi-
cation of virus from CD8 T cells and monocytes/mac-
rophages was unsuccessful in these subjects. Each of
these patients showed low to undetectable plasma viral
loads with moderate to high CD4 and CD8 T cell
counts. This provided some indication that infection of
CD8 T cells may be less likely to occur during low
plasma viremia and that the maintenance of elevated T
cell counts is an important factor in suppressing the
infection of CD8 T cells.
DISCUSSION
In this study we carried out a detailed investigation of
HIV variants in different blood compartments with em-
phasis on the distribution of drug resistance, trafficking
between cell-associated and cell-free viral compart-
ments, and the infection of CD8 T cells in vivo during
HAART. Although the compartmentalization of HIV-1 pop-
ulations in different anatomic compartments including
the brain, semen, gastrointestinal mucosa, cerebrospinal
fluid, plasma, and PBMC has been documented (Sim-
monds et al., 1991; Eyre et al., 2000; Smit et al., 2001;
Gupta et al., 2000; Romano et al., 1999; Poles et al., 2001;
Stingele et al., 2001; Wang et al., 2000), little is known
about the molecular nature of HIV variants in different
blood leukocytes during treatment with HAART. There-
fore, the aims of this study were (1) to examine the
distribution of drug-resistant HIV variants in different
blood cell types during HAART, and to identify those cell
type(s) which harbor drug-resistant viral populations; (2)
to examine the trafficking of HIV variants/resistant vari-
ants between cell-free and cell-associated compart-
ments during HAART; and (3) to investigate the nature of
viral strains derived from CD8 T cells and further clarify
the circumstances of CD8 T cell infection during
HAART.
To achieve these objectives, the protease and reverse
transcriptase genes of HIV-1 strains derived from
plasma, total PBMC, and individual blood cell types
(CD4 T cells, CD8 T cells, and monocyte/macro-
phages) were sequenced and analyzed for drug resis-
tance mutations in 13 patients receiving HAART. We
provide the first evidence of distinct viral populations
with characteristic patterns of drug resistance in differ-
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ent blood cell types during antiretroviral treatment. This
study included patients with a diverse range of clinical
features however, no significant correlation between
compartmentalization of viral quasispecies and the level
of plasma viremia or overall T cell counts was found.
Drug-resistant HIV strains were isolated from patients in
all viral load categories, including three in the BDL range
(400 copies/ml; patients 10, 11, and 12). Other studies
have also reported the emergence of antiretroviral resis-
tance when plasma viral load falls below 50 copies/ml
during HAART (Martinez-Picado et al., 2000) and these
findings are concordant with our observations.
The profile of drug resistance mutations in virus from
distinct blood compartments was variable in 5 of 13
individuals. The cumulative effects of this differential
distribution of drug resistance is likely to contribute to
the emergence of highly resistant variants in blood dur-
ing HAART. In general, there was more variation in the
level of resistance to reverse transcriptase inhibitors
than to protease inhibitors. The most notable feature of
subjects with compartmental variation in drug resistance
(patients 3, 4, 7, 8, and 10) was that viral strains derived
from CD8 T cells contained significantly less resis-
tance mutations to protease and/or reverse transcriptase
FIG. 3. Distance neighbor-joining trees showing phylogenetic relationships between the RT-protease nucleotide sequences of major viral
populations from different blood compartments in patients 1–10 (A–J, respectively).
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inhibitors (Table 2). In 2 cases (patients 3 and 8), several
additional mutations significantly increased the level of
drug resistance in virus derived from the monocyte/
macrophage compartment. These mutations were not
present in CD4 T cells or CD8 T cells, but were
observed in the plasma viral population. This suggested
trafficking of drug-resistant variants between plasma and
monocytes/macrophages in these patients. Analysis of
viral clones from patient 3 further confirmed the occur-
rence of viral trafficking between these compartments
(Fig. 2C). In contrast, 2 other subjects (patients 4 and 10)
showed increased drug resistance in the CD4 T cell
compartment, however, the additional mutations confer-
ring this resistance were notably absent in plasma. Our
data suggest that the concordance between cell-free
and cell-associated virus (both resistant and nonresis-
tant strains) may be a random phenomenon that is de-
pendent largely on host physiology or immunological
status at any given time during HAART treatment. The
pronounced segregation of plasma and total PBMC de-
rived viral clones observed in several patients (Figs.
2C–2E) provided evidence of a differential source of
plasma and PBMC viral strains in some cases. However,
the independent evolution of HIV-1 strains in specific
cellular compartments cannot be ruled out as a contrib-
uting element (Wong et al., 1997b).
The factors which influence the compartmentalization
of viral variants during HAART and the clinical and bio-
logical consequences are not fully understood. The ran-
dom nature of this compartmentalization suggests the
establishment of transitory drug-resistant reservoirs in
specific cell types at different stages of HAART treat-
ment. These transitory reservoirs may facilitate the shut-
tling of resistant variants between different anatomical
compartments and contribute to disease progression. A
number of factors may influence the compartmentaliza-
tion of drug resistant variants in different blood cell types
during HAART. Antiviral regimens may exert selective
pressures on HIV and affect the routing of viral variants
between anatomical compartments (Haddad et al., 2000;
Wang et al., 2000). Drug concentrations in vivo can vary
considerably from one tissue type to another during
antiretroviral treatment (Wong et al., 1997a; Kepler and
Perelson, 1998) and some anatomical compartments are
poorly accessible by different antiretroviral drugs (Over-
baugh et al., 1996; Hoetelmans, 1998). Likewise, the
penetration of antiretroviral drugs into different blood
cells types may be variable and alter the selective pres-
sures responsible for the emergence of drug-resistant
strains. Cellular immune responses during HAART also
impose selective pressures on HIV resulting in the dif-
ferential distribution of independently evolving vi-
rodemes in different anatomic compartments (Wong et
al., 1997b).
In contrast to the patients above, there was a uniform
distribution of drug resistance in different blood compart-
ments in a number of subjects (patients 1, 2, 5, 6, and 9).
This provided evidence that virus from each blood cell
compartment contributed similarly to the total PBMC and
plasma populations in these subjects. Viral drug resis-
tance in CD8 T cells was not reduced in these five
patients and was equivalent to that of virus from other
blood compartments. This provided evidence for the pro-
ductive infection of the CD8 T cell compartment in
these individuals. Viral clones from both the plasma and
total PBMC compartments in patients 1 and 2 showed
clear evidence of viral trafficking between plasma and all
three blood cell compartments (Figs. 2A–2B). It is unlikely
that the homogeneity of viral drug resistance observed in
these patients arose from impurities in separated cell
fractions. Four lines of evidence support the effective-
ness of cell separations in these patients. First, FACS
analysis revealed very low levels of contamination by
other cell types in each cell fraction (Fig. 1). Second,
sequences obtained from distinct cellular compartments
(particularly those from CD8 T cells) were notably dif-
ferent in many subjects, indicating that viral sequences
were derived from a different source. In those patients
with identical drug resistance mutations in each com-
partment, cell-specific variations in RT-PR peptide se-
quences that were unrelated to drug-resistance were
still observed (Table 3). Third, preliminary analysis of
viral envelope sequences indicated that viral populations
obtained from different cell compartments were distinct
(data not shown). Finally, the strong similarity between
viral clones derived from the total PBMC and plasma
viral populations of patients 1 and 2 (Figs. 2A and 2B)
provided evidence that viral sequences in different blood
cell compartments were homogeneous in some subjects
and did not arise from impurities in separated cell frac-
tions.
One of the primary goals of this study was to derive
further information on viral strains that infect CD8 T
cells and clarify the circumstances of CD8 T cell infec-
tion during HAART. The infection of CD8 T cells is of
particular importance because antiviral responses elic-
ited by these cells are vital to the long-term success of
HAART. There is considerable evidence that CD8 T
cells inhibit HIV-1 replication by both cytolytic and non-
cytolytic mechanisms (Walker et al., 1989). Chemokines
secreted by CD8 T cells including MIP-1, MIP1-, and
RANTES play a significant role in the suppression of
non-syncytium-inducing (NSI) strains of HIV in vitro by
blocking viral entry via the CC-chemokine receptor CCR5
(Cocchi et al., 1995; Deng et al., 1996). Until recently, the
infection of CD8 T cells remained controversial but
several studies have shown that they can be productively
infected in a strain-dependent manner (Saha et al., 2001;
Imlach et al., 2001). This infection may be mediated by
transient expression of the CD4 receptor during the dou-
ble positive stage of thymic maturation (Lee et al., 1997;
McBreen et al., 2001) or subsequent to activation of the
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T cell receptor complex (Imlach et al., 2001; Kitchen et al.,
1998; Flamand et al., 1998; Yang et al., 1998). These data
clearly demonstrate the infection of CD8 T cells during
HAART in 10 of 13 subjects. In addition, phylogenetic
analysis of reverse transcriptase and protease nucleo-
tide sequences indicated that HIV variants isolated from
CD8 T cells were distantly related to strains derived
from other blood cell types in patients 1, 2, 3, 6, 8, and 10
(Fig. 3), confirming the strain-specific infection of CD8
T cells in vivo.
At present, there is no clear explanation for the notable
absence of drug resistance mutations in virus derived
from CD8 T cells observed in some subjects (patients
3, 4, 7, 8, and 10). One possibility is that antiretroviral
drugs were less efficient in targeting CD8 T cells in
some individuals, leading to a decrease in the selective
pressure for the development of drug-resistant variants.
Alternatively, certain drug-resistant strains may not be
tropic for CD8 T cell entry. It is also conceivable that
these strains represent “archival species” established in
memory CD8 T cell subsets soon after primary sero-
conversion. Several studies have demonstrated that la-
tently infected memory CD4 T cells produce low levels
of virus capable of reseeding the body during successful
treatment with HAART (Wong et al., 1997a; Finzi et al.,
1997; Zhang et al., 1999; Furtado et al., 1999). This latent
viral reservoir is established soon after infection (Chun et
al., 1998a) and can be activated by proinflammatory cy-
tokines in vitro and potentially in vivo (Chun et al., 1998b).
Viral strains derived from latently infected CD4 T cells
have been shown to contain few antiretroviral drug re-
sistance mutations compared to the predominant viral
population, suggesting an absence of ongoing replica-
tion (Wong et al., 1997a; Zhang et al., 1998; Furtado et al.,
1999). The marked absence of drug resistance mutations
in the CD8 T cell viral population of several subjects
also indicated a lack of viral replication and raises the
possibility that, in some cases, memory CD8 T cells
may act as a latent viral reservoir. However, this was not
confirmed in this study because the individual contribu-
tion of the memory CD8 T cell subset was not as-
sessed. Other mechanisms including tissue distribution,
persistence, or slower replication could also account for
this phenomenon. In addition, CD8 T cell infection
appeared to be productive in a number of other cases
(patients 1, 2, 5, 6, and 9), further complicating this issue.
Nonetheless, the findings presented here on the infec-
tion of total CD8 T cell populations are of significant
biological relevance to the clinical management of HIV
patients. The protection of CD8 T cells from HIV-1
infection during HAART will lead to better T cell re-
sponses and is crucial for long-lasting natural immunity
in infected patients.
Our data suggest that CD8 T cell infection may
predominantly occur during intermediate or high levels
of plasma viremia, concurrent with a decline in CD4/
CD8 T cell counts. Subjects with higher viral loads
(patients 1–5) displayed a reduction in the number of
CD4 T cells and/or CD8 T cells (Table 1). Both cell
types play a crucial role in controlling the level of plasma
viremia, and this reduction may account for the infection
of CD8 T cells in these patients. Subjects with inter-
mediate or low viral loads generally displayed higher
CD8 T cell counts. In addition, plasma viremia was low
or undetectable and CD8 T cell counts were elevated
in the 3 patients from whom we failed to successfully
amplify HIV in the CD8 T cell compartment (patients 11,
12, and 13). These data suggest a correlation between
high overall T cell counts and the maintenance of below
detection to intermediate levels of plasma viremia during
HAART. The actual mechanism of CD8 T cell infection
is uncertain, however, HIV uses an array of measures to
interfere with the expression and production of essential
antiviral factors produced by CD8 T cells (Walker et al.,
1989). The ability of HIV to hinder the production and
maturation of key cytokines and chemokines signifi-
cantly contributes to deterioration of CD8 T cell re-
sponses during high plasma viremia. This was empha-
sized in a case study of 20 patients in which both the
number of CD8 T cells and the degree of CD8 T cell
TABLE 3
Variations in Protease/Reverse Transcriptase Peptide Sequences Not Related to Drug Resistance in Patients 1, 2, 5, 6, and 9
Patient Plasma PBMC CD4 T cells CD8 T cells Macrophages
1 PR 20: K/R 20: K/R 20: K/R 20: K 20: K
RT 177: E/K 177: E/K 177: K 177: K 177: E/K
2 PR 72: L 99: F 72: I/L 99: F 72: I 99: F 72: L 99: FS 72: L 99: F
RT 88: C/W 122: E/Q 88: C 122: E 88: C 122: Q 88: C 122: E 88: C 122: E
5 PR 64: M 65: E 64: M 65: E 64 M: 65: E 64: I/M 65: D/E 64: I/M 65: D/E
RT 35: V 50: I 35: I 50: I 35: I/V 50: I 35: V 50: I 35: V 50: I/S
6 PR 14: R 70: R 14: R 70: K 14: R 70: K 14: R 70: K 14: KR 70: K
RT 202: V 206: Q 202: I 206: Q 202: I 206: Q 202: I 206: Q 202: I 206: E/Q
9 PR 13: I 13: I/V 13: I/V 13: I 13: I
Note. PR, protease; RT, reverse transcriptase. Numbers refer to position of amino acid in peptide chain of the protein indicated. Single letter
abbreviation(s) following each number indicates the identity of amino acid at this position.
349CELLULAR DISTRIBUTION OF HIV-1 DRUG RESISTANCE DURING HAART
antiviral activity were shown to steadily decline during
prolonged HAART treatment (Imami et al., 2001) and may
explain why CD8 T cell antiviral responses are signif-
icantly reduced or lost under high viremia.
This study is the first to provide a detailed analysis of
viral strains isolated from different blood cell compart-
ments during highly active antiretroviral therapy. Our
data show that distinct viral populations harboring spe-
cific drug resistance mutations were present in different
blood compartments in some patients receiving HAART.
These findings also emphasize that both monocytes/
macrophages and CD4 T cells may serve as reservoirs
of drug-resistant viral strains during antiretroviral treat-
ment. The cellular and biological consequences of the
compartmentalization of drug resistance viral variants
during HAART remain unclear and may have important
implications for future design of antiretroviral treatment
strategies. Few studies have addressed the HIV-1 infec-
tion of CD8 T cells. Our data clearly demonstrated the
infection of CD8 T cells in vivo in subjects with a
diverse range of plasma viremia and CD4 T cell counts.
In several patients, CD8 T cells also showed markedly
lower levels of viral drug resistance, indicating a lack of
viral replication. We found clear evidence suggesting
that viral infection of CD8 T cells in vivo occurs in a
strain-dependent manner, and propose that a significant
correlation may exist between the infection of this com-
partment and the level of plasma viremia and/or overall
T cell counts. In view of these findings, future studies
addressing the timing, mechanisms, and effects of
CD8 T cell infection are essential to develop treat-
ments that can assist in the recovery of CD8 T cell
antiviral responses during HAART. Further, the infection
of CD8 T cells may provide a marker to predict the
long-term efficacy of HAART treatment. Although the ef-
fect of the emergence of drug-resistant HIV variants on
the outcome of antiretroviral treatment is clear, the actual
clinical and biological relevance of the cellular compart-
mentalization of drug-resistant strains remains to be es-
tablished. Clarification of these aspects of infection will
benefit future treatment strategies for HIV patients.
MATERIALS AND METHODS
Study population
Thirteen HIV-1 seropositive patients with a range of
different plasma viremia and CD4 T cell counts were
enrolled in this study. Treatment histories and clinical
profiles are shown in Table 1. A single blood sample was
collected from each individual after informed consent. All
subjects (with the exception of patient 5) were receiving
HAART at the time of sampling. Plasma viral loads were
determined by using a commercially available assay
(Amplicor HIV-1 Monitor Test Version 1.0; Roche, Castle
Hill, NSW, Australia).
Cell separations
Samples (10–20 ml) of whole blood anticoagulated
with EDTA were obtained from each patient. Samples
were diluted with an equal volume of phosphate-buffered
saline (PBS) and peripheral blood mononuclear cells
(PBMC) isolated by Ficoll–Hypaque density gradient cen-
trifugation (Amersham Pharmacia Biotech, Uppsala,
Sweden). Individual blood cell types (CD4 T cells,
CD8 T cells, and monocytes/macrophages) were sep-
arated by positive isolation using antibody-conjugated
magnetic beads (Dynal Biotech, Oslo, Norway) as per
manufacturer’s instructions.
Fluorescence-activated cell sorting (FACS) analysis
CD4 T cells and CD8 T cells were separated from
freshly isolated PBMC and rested overnight in culture
medium (RPMI/10% FCS). Both R-phycoerythin (R-PE)-
conjugated CD4 antibody (clone S3.5, 5 l per 105 cells;
Caltag Laboratories, Burlingame, CA) and fluorescein
isothiocyanate isomer 1 (FITC)-conjugated CD8 antibody
(clone 3B5, 5 l per 105 cells; Caltag Laboratories) were
added to each cell suspension. R-PE-conjugated mouse
IgG2a antibody (clone UPC-10, 10 l per 105 cells: Caltag
Laboratories) and FITC-conjugated mouse IgG2a anti-
body (clone UPC-10, 10 l per 105 cells; Caltag Labora-
tories) were used as isotype controls for both CD4 T
cell and CD8 T cell fractions. After incubation for 30
min at 4°C, cells were washed twice in PBS and fixed in
200 l of 1% paraformaldehyde. The purity of each cell
population was determined using a FACScan (Becton–
Dickinson, Franklin Lakes, NJ) and analyzed with
CellQuest V3.3 software (Becton–Dickinson).
Nucleic acid extraction and PCR amplification
DNA was isolated using a QIAamp DNA mini kit (Qia-
gen, Valencia, CA) according to the manufacturer’s pro-
tocol. RNA was isolated from plasma using TRI reagent
(Sigma, St. Louis, MO) and reverse-transcribed into
cDNA with Superscript II (GIBCO/BRL, Rockville, MD) as
per manufacturer’s instructions. A nested polymerase
chain reaction (PCR) was used to amplify a 1099-bp
region of the HIV genome containing the reverse tran-
scriptase (RT) and protease (PR) genes using primers
5-GAAGAGACAGCAACTCCCTCTCAG-3 (outer, sense),
5-GCCCAATTCAATTTTCCCACTAAC-3 (outer, antisense),
5-GACAAGGAACTGTATCCTTTAGCTTC-3 (inner, sense),
and 5-TTCTGTATGTCATTGACAGTCCAGCT-3 (inner, anti-
sense). Both primary and secondary PCR reactions
contained 2 units of Taq DNA polymerase (Promega,
Madison, WI), 1 PCR buffer (Promega: 1 mM Tris–HCl,
5 mM KCl, 0.1% Triton X-100), 2.5 mM MgCl2, 200 M of
each dNTP, and 0.4 M of each primer in a total volume
of 50 l. Thermocycling conditions were as follows: 95°C
for 2 min and then 35 cycles of 94°C for 30 s, 55°C for
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30 s, and 72°C for 1.5 min, followed by a final extension
step at 72° for 10 min. PCR products were resolved using
1% agarose gels containing 0.5 g ethidium bromide and
visualized under UV light.
Cloning of PCR products
PCR-amplified DNA was ligated into pGEM-T Easy
vectors (Promega), transformed into competent cells (JM
109; Promega), and plated on Luria–Bertani (LB) plates
(50 g ampicillin/ml). Single white colonies were re-
plated on fresh LB plates and incubated overnight at
37°C. Colonies were screened by PCR (same primers/
conditions as above) and sequencing carried out on
mini-prep-extracted DNA.
Sequence analyses
Dideoxynucleotide sequencing reactions were carried
out using an ABI Prism Big-Dye Terminator Cycle Se-
quencing Ready Reaction kit V3.0 (Applied Biosystems,
Scoresby, Vic, Australia) as per manufacturer’s instruc-
tions and sequenced on an ABI 3100 DNA sequencer
(Applied Biosystems). Drug resistance profiles were gen-
erated using the Stanford HIV database (http://hivdb.
stanford.edu/). Sequences were aligned with CLUSTALW
(Higgins et al., 1992; Thompson et al., 1994) available
through ANGIS (http://www.angis.org.au). Phylogenetic
analyses were performed using programs from the
PHYLIP package (Felsenstein, 1989) also available
through ANGIS.
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